| Type of cancer |
Effects of IDO in experimental models |
Correlation of IDO expression with clinical outcome |
| [References] |
(Methods of evaluation) |
(Methods of evaluation, n = sample number) |
| Endometrial cancer [25] |
N.D. |
Impaird OS and PFS in stage I-IV patients (IHC, n = 80) |
| Endometrial cancer [28] |
N.D. |
Reduced infitration of CD8 + TIL and CD57 + NK(IHC, n = 65) |
| Endometrial cancer [29] |
Induces tumor growth and inhibits NK(in tumor-xenografted mice) |
N.D. |
| Ovarian cancer [32] |
Increases intraperitoneal dissemination(in tumor-xenografted mice) |
Reduced CD8 + TIL and impaired OS and PFS(IHC, n = 60) |
| Ovarian cancer [30] |
Correlates with chemoresistance to paclitaxel (microarray gene profiling and PCR) |
Impaired OS in stage III-IV serous adenocarcinoma(IHC, n = 24) |
| Ovarian cancer [31] |
N.D. |
Impaired OS in stage III-IV serous adenocarcinoma(IHC, n = 33) |
| Ovarian cancer [35] |
Suppresses T-cell proliferation(in vitro) |
N.D. |
| Ovarian cancer [33] |
Increases tumor growth and inhibits NK(in tumor-xenografted mice) |
N.D. |
| Cervical cancer [37] |
N.D. |
Impaird OS and DFS in stage IB-IIB cervical cancer(IHC, n = 112) |
| Cervical cancer [38] |
N.D. |
Progression from CIN2/3 to microinvasive carcinoma(IHC, n = 46) |
| Vulvar cancer [39] |
N.D. |
Impaird OS in vulvar squamous cell carcinoma(IHC, n = 76) |
| Vulvar cancer [40] |
N.D. |
No association with the number of CD8 + TIL or Treg(IHC, n = 286) |
N.D: Not Done; OS: Overall Survival; PFS: Progression-free Survival; DFS: Disease-free Survival; IHC: Immunohistochemistry; TIL: Tumor-infiltrating Lymphocyte; NK: Natural Killer Cell; Treg: Regulatory T cell; CIN: Cervical Intraepithelial Neoplasia